EUVIMEDEUVIMED entdecken
Crossref

Discovery and Characterization of Selective, First-in-Class Inhibitors of Citron Kinase

Joshua J Maw, Jesse A Coker iD, Tarun Arya, Christopher M Goins iD, Dhiraj Sonawane iD, Sang Hoon Han, Matthew G Rees, Melissa M Ronan, Jennifer A Roth, Nancy S Wang, Hannelore V Heemers, Jonathan D Macdonald iD und 1 weitere

Journal of Medicinal Chemistry · 22.02.2024 · 67 (4) · 2631-2666

DOI: 10.1021/acs.jmedchem.3c01807 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 08.02.2024. Verfasst von Joshua J Maw und 12 weiteren Autor:innen. Beteiligte Einrichtung: Center for Therapeutics Discovery, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio 44195, United States. Hauptthemen laut MEDLINE: Protein Serine-Threonine Kinases, Cytokinesis. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Dr. Ralph and Marian Falk Medical Research Trust, Lerner Research Institute, Cleveland Clinic, Cleveland Clinic Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Citron kinase (CITK) is an AGC-family serine/threonine kinase that regulates cytokinesis. Despite knockdown experiments implicating CITK as an anticancer target, no selective CITK inhibitors exist. We transformed a previously reported kinase inhibitor with weak off-target CITK activity into a first-in-class CITK chemical probe, C3TD879. C3TD879 is a Type I kinase inhibitor which potently inhibits CITK catalytic activity (biochemical IC50 = 12 nM), binds directly to full-length human CITK in cells (NanoBRET Kd 17-fold versus 373 other human kinases), making C3TD879 the first chemical probe suitable for interrogating the complex biology of CITK. Our small-molecule CITK inhibitors could not phenocopy the effects of CITK knockdown in cell proliferation, cell cycle progression, or cytokinesis assays, providing preliminary evidence that the structural roles of CITK may be more important than its kinase activity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Serine-Threonine KinasesCytokinesisHumansCell DivisionPhosphorylationCell Proliferation

Substanzen

Protein Serine-Threonine Kinases

Autor:innen und Institutionen

  • Center for Therapeutics Discovery, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio 44195, United States.
  • Broad Institute of MIT and Harvard, 415 Main Street, Cambridge Massachusetts 02142, United States.
  • Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio 44195, United States.

ORCID-Profile: Jesse A Coker, Christopher M Goins, Dhiraj Sonawane, Jonathan D Macdonald, Shaun R Stauffer

Förderung

  • Dr. Ralph and Marian Falk Medical Research Trust
  • Lerner Research Institute, Cleveland Clinic
  • Cleveland Clinic Foundation

Zitieren

APA

Maw, J. J., Coker, J. A., Arya, T., Goins, C. M., Sonawane, D., Han, S. H., Rees, M. G., Ronan, M. M., Roth, J. A., Wang, N. S., Heemers, H. V., Macdonald, J. D., & Stauffer, S. R. (2024). Discovery and Characterization of Selective, First-in-Class Inhibitors of Citron Kinase. Journal of Medicinal Chemistry, 67(4), 2631-2666. https://doi.org/10.1021/acs.jmedchem.3c01807

Vancouver

Maw JJ, Coker JA, Arya T, Goins CM, Sonawane D, Han SH, et al. Discovery and Characterization of Selective, First-in-Class Inhibitors of Citron Kinase. Journal of Medicinal Chemistry. 2024;67(4):2631-2666. doi:10.1021/acs.jmedchem.3c01807

BibTeX
@article{Maw2024,
  author = {Maw, Joshua J and Coker, Jesse A and Arya, Tarun and Goins, Christopher M and Sonawane, Dhiraj and Han, Sang Hoon and Rees, Matthew G and Ronan, Melissa M and Roth, Jennifer A and Wang, Nancy S and Heemers, Hannelore V and Macdonald, Jonathan D and Stauffer, Shaun R},
  title = {Discovery and Characterization of Selective, First-in-Class Inhibitors of Citron Kinase},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  volume = {67},
  number = {4},
  pages = {2631--2666},
  doi = {10.1021/acs.jmedchem.3c01807}
}
Kostenlos starten →